pubrio
BeiGene logo

BeiGene

Public
+1
beigene.com
Biotechnology Research3,000+ employeesFounded 2010🇺🇸 United States

Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible. To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.

Founded
2010
Employees
3,000+
Industry
Biotechnology Research
Company type
Public Company
Stock
nasdaq: BGNE
Headquarters
🇺🇸Cambridge, MA (+21)
Specialties
PharmaceuticalsBiotechnologyHealthcareBiotechnology Research
3 / 13
Active markets
Japan · Switzerland · Taiwan
1
New markets
Hong Kong SAR China
Low
Confidence
mostly early signals
+100%
Momentum
vs prior period
30 / 100
Expansion Score
Developing
Stages3Exploring9Investing1Landing
3 signals · Last 90 days

Global expansion

Live
JapanSwitzerlandTaiwan
Stages
ExploringInvestingLandingOperating
+10more marketsLocked
3 of 13 shown

Unlock the market timeline & signal feed

Activity pulse

New Hiring activity — 1 fresh signal just appeared.

Last 90 days
Hiring
1New
Hiring
Marketing & PR
0
No activity
Product & Tech
1New
Product launch
+2more categoriesLocked
3 of 5 shown

Market entry timeline

The order this company entered each market — oldest to newest

1
🇨🇭Switzerland1st market entered · 2024Advancing
Investing
17 signalsInvesting stage
2
🇯🇵Japan2nd market entered · 2024Advancing
Investing
26 signalsInvesting stage
3
🇹🇼Taiwan3rd market entered · 2024Advancing
Exploring
14 signalsExploring stage
+10more marketsLocked
3 of 13 shown
Current stageLandingSetting up on the ground
Confidence35%Low
Tracking since2024first signal

Recent signals

Hiring🇭🇰 Hong Kong SAR Chinalast wk.

Zhang Jinwei Joins HKBMIA Board

Office lease🇸🇬 Singaporelast mo.

BPD Conference Expands Global Biopharmaceutical Network

Sign up to see the full signal feed

Good to know

Frequently Asked Questions Regarding BeiGene

Quick answers about BeiGene's business, markets, and growth signals.

Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated global rebranding to BeOne Medicines Ltd. and redomiciliation to Switzerland, pending shareholder approval. The new name reflects our commitment to develop innovative medicines and partner with the global community to help as many patients with cancer as possible. To learn more about BeOne Medicines, please follow our new LinkedIn profile @BeOne Medicines.

Start your journey today

Start with the platform — or start with a conversation

Use Pubrio on your own, or let our team help you with research, lead generation, or data integration.

Start Journey Image
pubrio

Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.​

© 2026 Pubrio. All rights reserved.